Daily Bulletin

Men's Weekly

.

New data independently confirms and extends laboratory findings and expands safety profile of ATH434-PR Newswire APAC

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
Cision

MELBOURNE, Australia and SAN FRANCISCO, Aug. 4, 2020 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced that new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for presentation at the 2020 International Congress of...

Read more: New data independently confirms and extends laboratory findings and expands safety profile of...

More Articles ...

  1. Tile™ and Skullcandy Create Most Advanced True Wireless Finding Experience-PR Newswire APAC
  2. Trade360 Announces New Trading Platform-PR Newswire APAC
  3. Alterity Releases Appendix 4C - Q4 FY20 Quarterly Cash Flow Report-PR Newswire APAC

Business News

Strategic partnerships to enable global acceleration for Aussie fashion brands: SHEIN Xcelerator launches

SHEIN Xcelerator is introducing a more agile, demand-led operating model, allowing brands to scale while retaining control over creative direction and identity. For fashion brands, the pressure t...

Daily Bulletin - avatar Daily Bulletin

Tips for Avoiding Probate Delays

Probate can be a lengthy process at the best of times, and delays often compound the stress that comes with managing a loved one's estate. Many of those delays are avoidable with the right preparati...

Daily Bulletin - avatar Daily Bulletin

Integrating Marketing Automation Workflows with Headless CMS: Creating a Unified Engine for Scalable Growth

Marketing automation is a necessary component of modern engagement with customers. Automated emails, triggered campaigns, lead nurturing and lifecycle messaging enable brands to scale their messagin...

Daily Bulletin - avatar Daily Bulletin

Speed Dating For Business